^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    lonigutamab ugodotin (W0101)

    i
    Other names: W0101, W-0101, ADC W010
    Company:
    Pierre Fabre, Roche
    Drug class:
    Microtubule inhibitor, IGF-1R-targeted antibody-drug conjugate
    Related drugs:
    12d
    A Study of a New Investigational Medicinal Product to Treat Patients with Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=316, Terminated, Pierre Fabre Medicament | Active, not recruiting --> Terminated; delay in participants recruitment in cohort A3 and IMP manufacturing issues
    Trial termination • Metastases
    |
    lonigutamab ugodotin (W0101)